AgomAb Therapeutics NV AGMB
5.62 USD -0.20 (-3.44%)
Regular-session close
5.72 +0.10 +1.78%
After hours · Nov 19, 4:24 PM ET
5.59 Day range 6.00
5.50 52-week range 17.82
- YTD
- -61.64%
- 1 year
- -61.64%
No chart data for this range yet.
- Market cap
- 276.77M
- EPS (ttm)
- -2.08
- YTD return
- -61.64%
- 1-year return
- -61.64%
- Volume
- 335.90K
- Avg volume
- 203.29K
- Open
- 5.85
- Previous close
- 5.82
- Day's range
- 5.59 – 6.00
- 52-week range
- 5.50 – 17.82
Fundamental scorecard
3 of 25 checks passed on AGMB’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
AGMB Revenue — quarterly 0
AGMB Net income — quarterly -17.40M
AGMB EPS — quarterly -4.34
News
Agomab to Participate in Upcoming Investor Conferences
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Average Target Price of $37.50
AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Agomab to Participate in Upcoming Investor Conferences
Your note
Sign in to keep a note on AGMB — it syncs with the Stock Master app.
